Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA

< Previous 1 2 3 4 Next >
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
From VALNEVA
Via GlobeNewswire
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million
From VALNEVA
Via GlobeNewswire
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
From VALNEVA
Via GlobeNewswire
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
From VALNEVA
Via GlobeNewswire
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India
From VALNEVA
Via GlobeNewswire
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
From VALNEVA
Via GlobeNewswire
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
From VALNEVA
Via GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
From VALNEVA
Via GlobeNewswire
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
From VALNEVA
Via GlobeNewswire
Valneva Hosts Investor Day in New York City
From VALNEVA
Via GlobeNewswire
Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
From VALNEVA
Via GlobeNewswire
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
From VALNEVA
Via GlobeNewswire
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
From VALNEVA
Via GlobeNewswire
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
From VALNEVA
Via GlobeNewswire
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
From VALNEVA
Via GlobeNewswire
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
From VALNEVA
Via GlobeNewswire
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
From VALNEVA
Via GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
From VALNEVA
Via GlobeNewswire
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
From VALNEVA
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.